ALA-3000 vs Blixeprodil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
ALA-3000
Developed by Alar Pharmaceuticals
NCT06965569 · Phase 1 · completed
This randomized, double-blind, placebo-controlled multiple-dose study gave subcutaneous ALA-3000 or placebo, with a standard oral antidepressant, to patients with treatment-resistant depression. All of its primary measures were safety and tolerability measures, which have no formal efficacy test, so there is no met or missed result. The company reports that side effects were mild to moderate and that no dissociation, sedation or psychosis-like symptoms were seen. Effects on depression scores were exploratory. The figures come from the company's press release.
Reported efficacy
Incidence of treatment-related adverse events (AEs) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal orthostatic blood pressure (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal heart rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal blood oxygen saturation (pulse oximetry) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal respiratory rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal body temperature (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal 12-lead electrocardiogram (ECG) parameters (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal hematologic findings (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal serum chemistry test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine cytologic findings (Baseline (prior to dosing) and the End of Study (Day 36) visit); Incidence and severity of dissociative symptoms assessed by Clinician Administered Dissociative States Scale (CADSS) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of treatment-emergent sedation assessed by Modified Observer's Assessment of Alertness/ Sedation (MOAA/S) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of potential withdrawal symptoms assessed by Physician Withdrawal Checklist; 20-item (PWC-20) (Two weeks after last investigational product administration and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of suicide ideation assessed by Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of four-item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination); Injection site tolerability based on injection site grading scale (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site pain visual analog scale (VAS) (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site evaluation for potential reactions and evidence of removal (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit): Primary, safety and tolerability (no formal efficacy test): treatment-related adverse events were mild to moderate in severity, and no dissociation, sedation or psychosis-like symptoms were observed. (not_applicable)
Result source: NCT06965569
Blixeprodil
Developed by Gilgamesh Pharma
NCT06309277 · Phase 2 · completed
This two-part, randomized, quadruple-blind, placebo-controlled Phase 2a study gave single and multiple oral doses of GM-1020 (blixeprodil) or placebo to 46 patients with major depressive disorder. The only registered primary outcome is the incidence of treatment-emergent adverse events, which has no formal efficacy test, so there is no met or missed result. Antidepressant response was a preliminary, non-primary aim. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Incidence of Treatment Emergent Adverse Events (Baseline, Day 29): Primary outcome, incidence of treatment-emergent adverse events to Day 29 (no formal efficacy test): Part A, 23 participants on placebo and 43 on GM-1020 140 mg with at least one TEAE (CT.gov posted results). (not_applicable)
Result source: NCT06309277
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALA-3000 | Blixeprodil |
|---|---|---|
| MADRS, change (acute) | —Not reported | -10.5 vs -5.4−5.1 vs placeboNCT063092771 other result
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- ALA-3000
- —Not reported
- Blixeprodil
- -10.5 vs -5.4−5.1 vs placeboNCT06309277
1 other result
- -12.1 vs -5.8 NCT06309277
CGI-S, change (acute)
- ALA-3000
- —Not reported
- Blixeprodil
- —Not reported
MADRS response
- ALA-3000
- —Not reported
- Blixeprodil
- —Not reported
MADRS remission
- ALA-3000
- —Not reported
- Blixeprodil
- —Not reported
Relapse (% of patients)
- ALA-3000
- —Not reported
- Blixeprodil
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALA-3000: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ALA-3000: 0 of 4 rows · Blixeprodil: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Blixeprodil |
|---|---|
| Dropout rate | —210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results—140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | —210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results—140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Serious AEs | 0%210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | 210 mg time perception altered 63.2% (placebo 0%) euphoric mood 57.9% (placebo 0%) hallucination, visual 57.9% (placebo 0%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results140 mg dizziness 46.5% (placebo 4.5%) euphoric mood 44.2% (placebo 0%) headache 37.2% (placebo 18.2%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 140 mg euphoric mood 61.1% (placebo 0%) dizziness 50% (placebo 4.5%) headache 50% (placebo 18.2%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Blixeprodil
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALA-3000's landscape · Blixeprodil's landscape